Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings Corp
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for TLX591
Telix AGM – Chairman and CEO Addresses
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing site.
Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product
Telix has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx
Seneffe Manufacturing Facility – Shareholder Walkthrough
Telix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing facility
Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology.
Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call
Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with investors.
Activity Report and Sales Note to Accompany Appendix 4C
Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product